Contact this trialFirst, we need to learn more about you.
Janus Kinase (JAK) Inhibitor
Ruxolitinib for Polycythemia Vera
Recruiting3 awardsPhase 2
Boston, Massachusetts
This trial will assess the efficacy of ruxolitinib in reducing symptoms in patients with low-risk essential thrombocythemia (ET) or polycythemia vera (PV).
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.